Immune checkpoint blockade (ICB) therapy such as PD-1-PD-L1 blockade has shown efficacy in microsatellite instability (MSI) CRC, which can produce more neoantigens, thereby increasing the likelihood of tumor immune recognition [2]. Here, CD274 is linked to colorectal carcinoma.